Dr Helen Prior

Position

Programme Manager - Drug development

LinkedIn

https://www.linkedin.com/in/helen-prior-aa060a95

Email address

helen.prior@nc3rs.org.uk


Helen is the lead for a new collaboration with the ABPI on applying the 3Rs in pharmaceutical development. She is a member of the Innovation and Translation Group. Helen has previously collaborated on behalf of the Safety Pharmacology Society (SPS) on a project with the NC3Rs on social housing of non-rodents during telemetry studies.

View Helen's office-led projects.

External roles

NC3Rs publications

Jackson S, Prior H and Holmes A (2018). The use of human tissue in safety assessment. Journal of Pharmacological and Toxicological Methods (in press) doi: 10.1016/j.vascn.2018.05.003

Prior H, Baldrick P, de Hann L, Downes N, Jones K, Mortimer-Cassen E and Kimber I (2018).  Reviewing the utility of two species in general toxicology related to drug development.  International Journal of Toxicology 37: 121-124 doi: 10.1177/1091581818760564.

Prior H, Sewell F, Stewart J (2017). Overview of 3Rs opportunities in drug discovery and development using non-human primates. Drug Discovery Today: Disease Models. (in press) doi: 10.1016/j.ddmod.2017.11.005

Sewell F, Edwards J, Prior H and Robinson S (2016). Opportunities to Apply the 3Rs in Safety Assessment Programs. ILAR Journal 57 (2): 234–245 doi: 10.1093/ilar/ilw024.

Prior H, Bottomley A, Champéroux P, Cordes J, Delpy E, Dybdal N, Edmunds N, Engwall M, Foley M, Hoffmann M, Kaiser R, Meecham K, Milano S, Milne A, Nelson R, Roche B, Valentin JP, Ward G, Chapman K (2016). Social housing of non-rodents during cardiovascular recordings in safety pharmacology and toxicology studies. Journal of Pharmacological and Toxicological Methods 81:75-87 doi: 10.1016/j.vascn.2016.03.004

For publications, see Helen's ResearchGate profile.

Qualifications

PhD, Cardiovascular Pharmacology
University of Leeds 1994 – 1997
K+ channel subtypes and adenosine A2A receptors in rabbit renal arcuate artery